Table 1 Drug impact on EGF-induced fast signaling in SKBR3 cells (% AU)

From: Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs

 

0 min

12 min EGF

30 min EGF

 

pERK

pAKT

pERK

pAKT

pERK

pAKT

Control

6.6

34.3

87.5

97.2

100.0

98.8

E

0

6.2

30.9

39.5

14.6

35.7

T

10.8

7.2

82.0

68.3

77.8

46.4

P

16.5

25.0

71.3

52.5

66.3

38.2

ET

1.1

2.5

35.0

19.8

2.6

0

EP

0.6

5.1

32.8

31.3

1.9

8.6

TP

26.8

11.2

66.3

42.1

59.7

26.0

TPE

4.6

5.2

42.3

10.6

11.2

6.2

  1. Abbreviations: EGF, epidermal growth factor; E, erlotinib; EP, erlotinib+pertuzumab; ET, erlotinib+trastuzumab; P, pertuzumab; T, trastuzumab; TP, trastuzumab+pertuzumab; TPE, trastuzumab+pertuzumab+erlotinib.
  2. Impact of E, T, P and combinatorial drug treatments (ET, EP, TP and TPE) on fast signaling in SKBR3 cells (Figure 2). The median of normalized triplicate measurements was used to calculate the impact of drug on cellular signaling. Scales ranging 0–100% were generated target protein-specific. Maximal readings of normalized fluorescent intensities of a certain time course were set to equal 100% and the minimum was set to equal 0%.
Back to article page